

A Novel Tri-Modal Viral–Ultrasound Gene-Delivery Therapy Protocol for Lysosomal Neurodegeneration via Stochastic Model Optimization with Uncertainty Quantification and Generalizability

Kartheek Nekkanti² & Chandrajit Bajaj¹

¹Oden Institute for Computational Engineering and Sciences,
The University of Texas at Austin, Austin, TX 78712, USA

²Pearson Ranch Middle School,
Round Rock Independent School District, Austin, TX 78717, USA

May 20, 2026

Abstract

We present a computationally optimized tri-modal framework integrating AAV-T4 gene delivery, substrate reduction therapy (SP2/SRT), and focused ultrasound (FUS) blood–brain barrier (BBB) modulation for GM2 gangliosidosis (Tay-Sachs / Sandhoff disease) and nine additional lysosomal storage disorders (LSDs). A 16-dimensional Itô stochastic differential equation (SDE) system, calibrated from 15 public genomic and proteomic datasets and integrated via the Milstein scheme ($N = 1,000$ realizations, $\Delta t = 0.1$ d), demonstrates that tri-modal therapy reduces mean brain GM2 burden from 890 nmol/g to 180 ± 35 nmol/g (75.7%; 95% CI [74.2%, 77.2%]) versus 30–35% for SRT monotherapy and 40–50% for AAV monotherapy, with neuroinflammation suppression of 95–97% and Bayley-III motor/cognitive advantages of +49/ +21 points at day 365. Global Sobol analysis identifies BBB entry kinetics ($k_{T4,\text{entry}}$, $S_T = 0.909$, 95% CI [0.88, 0.94]) as the singular rate-limiting parameter, exceeding enzymatic degradation capacity ($V_{\max,B}$) by 13.0-fold (total-order) and 16.5-fold (first-order), thereby establishing GM2 gangliosidosis as *delivery-limited* rather than enzyme-limited. Six-region neuroanatomical validation confirms uniform 80–89% GM2 reduction (mean $86.2 \pm 3.2\%$, $\text{CV} = 3.7\%$), validating the lumped-compartment approximation. Modular substitution of four disease-specific parameters across nine LSDs reproduces consistent BBB-bottleneck dominance ($S_T = 0.82\text{--}0.91$) with $\approx 90\%$ parameter reuse, establishing broad translational reach. All derivations, numerical implementation details, convergence analyses, and supplementary simulations are provided in full in the appendices.

Keywords: Lysosomal storage disorders · GM2 gangliosidosis · Tay-Sachs / Sandhoff disease · Gene therapy · Focused ultrasound · Blood–brain barrier · Itô SDEs · Milstein scheme · Sobol sensitivity analysis · Stochastic modeling · Neuroinflammation · Bayley-III scales · Translational neuroscience

1 Introduction

1.1 Clinical Background and Unmet Need

Lysosomal storage disorders (LSDs) are a heterogeneous class of more than 70 inherited metabolic diseases caused by deficient lysosomal enzyme activity, leading to intralysosomal accumulation of undegraded substrates, secondary neuroinflammation, and progressive neuronal death [Sandhoff & Harzer, 2013, Bley et al., 2011, Wada et al., 2000, Jeyakumar et al., 1999]. Collectively, one in 7,700 live births carries a pathogenic allele for at least one LSD [Boycott et al., 2013, Bley et al., 2011]. The neurotropic variants impose particular translational difficulty: the blood–brain barrier (BBB) limits systemic drug delivery, neuronal populations are largely post-mitotic and therefore non-regenerating, and infantile-onset forms progress over months.

We focus on **GM2 gangliosidosis** (Tay-Sachs disease: *HEXA* mutations; Sandhoff disease: *HEXB* mutations; AB variant: *GM2A* mutations), the archetype of fatal infantile neuronal LSDs. Loss of β -hexosaminidase causes intraneuronal GM2 accumulation reaching 800–1,300 nmol/g [Bley et al., 2011, Cachón-González et al., 2006], microglial activation above a threshold $G_{th} \approx 500$ nmol/g [Jeyakumar et al., 1999], and median survival under four years with no approved therapy [Sandhoff & Harzer, 2013, Bley et al., 2011].

1.2 Why Monotherapy Is Insufficient: A Formal Bottleneck Analysis

Three mechanistically non-redundant rate-limiting steps must be addressed concurrently for meaningful substrate clearance, and no mono- or bi-modal therapy closes all three simultaneously. The first bottleneck is continuous substrate synthesis: even with fully restored enzymatic machinery, $g_{synth} \approx 3$ nmol/g/d maintains a positive accumulation flux. Substrate reduction therapy (SRT; miglustat, eliglustat) inhibits glucosylceramide synthase and can reduce this flux by up to 35% in murine Sandhoff models [Jeyakumar et al., 2005, Bembi et al., 2006], but this is insufficient to drive net substrate clearance when the enzymatic deficit remains unaddressed. The second bottleneck is the absent lysosomal enzyme itself. AAV-mediated *HEXA*/*HEXB* transgene delivery can restore β -hexosaminidase activity and achieves 40–50% GM2 reduction intracranially [Cachón-González et al., 2006]; however, with $G_B = 800$ –1,300 nmol/g far exceeding $K_{m,B} \approx 300$ nmol/g, Michaelis–Menten kinetics saturate at $V_{max,B}$, and transgene expression alone cannot exceed this ceiling clearance rate regardless of dose. The third bottleneck is the BBB’s near-impermeability to AAV: intravenous delivery achieves < 1% CNS penetration [Haery et al., 2019, Gray et al., 2011a], so the systemic vector load required to achieve therapeutically meaningful CNS transduction is orders of magnitude above what is safely deliverable. Pulsed focused ultrasound with microbubbles transiently disrupts tight junctions via acoustic cavitation, enhancing CNS delivery 10–100-fold [Treat et al., 2007, Wang et al., 2015], but FUS alone supplies no therapeutic enzyme.

No bi-modal combination closes all three bottlenecks: SRT + AAV addresses synthesis and enzyme absence but not transport; SRT + FUS addresses synthesis and transport but not the absent enzyme; AAV + FUS addresses enzyme absence and transport but not synthesis flux. Only the tri-modal combination (SRT + AAV + FUS) simultaneously reduces synthesis, restores enzyme, and amplifies transport, yielding a synergy index of 1.47 and disrupting the microglial feedback loop ($G_B > G_{th}$) to produce 95–97% neuroinflammation suppression. This mechanistic necessity motivates the model architecture described in Section 3.

1.3 Stochastic Modeling as Translational Strategy

With fewer than 100 annual new cases in the US and Europe combined [Boycott et al., 2013, Bley et al., 2011], prospective randomized trials for GM2 gangliosidosis are both statistically underpowered and ethically untenable. We therefore adopt Itô SDEs as the modeling substrate, augmenting deterministic dynamics with multiplicative Wiener-process noise ($CV \approx 10\%$) to represent inter-individual biological variability [Øksendal, 2003]. Global Sobol sensitivity analysis [Saltelli, 2002]—a variance-based decomposition assigning fractional contributions of each parameter to output uncertainty—is then applied to identify the dominant bottleneck and guide intervention prioritization.

1.4 Scope and Organization of This Work

The core technical product of this paper is a 16-dimensional Itô SDE system that simultaneously encodes SRT pharmacokinetics, AAV-T4 CNS delivery amplified by FUS, GM2 biochemistry, neuroinflammatory feedback, Bayley-III clinical trajectories, secondary endpoints, and anti-capsid immunogenicity. Integrated via the Milstein scheme across $N = 1,000$ independent realizations, the model produces a 75.7% mean GM2 reduction from 890 nmol/g to 180 ± 35 nmol/g under tri-modal therapy, with 95–97% neuroinflammation suppression and Bayley-III motor/cognitive advantages of +49/+21 points at day 365, while strictly preserving the ordering $NH < mono < bi < tri$ across all realizations.

Global Sobol sensitivity analysis then provides the quantitative argument for why the model behaves this way. The BBB entry rate $k_{T4,entry}$ controls $S_T = 0.909$ of terminal GM2 outcome variance— $13.0\times$ the contribution of enzymatic degradation capacity $V_{max,B}$ —demonstrating that the disease operates in a saturated Michaelis–Menten regime where improvements in enzyme kinetics yield negligible gains. This delivery-limitation finding holds with > 10 -fold margin across the full Sobol parameter range, and is independently reproduced across nine LSDs ($S_T = 0.82$ – 0.91) using a modular architecture that requires only four disease-specific parameter substitutions and reuses $\approx 90\%$ of the GM2 calibration. Six-region spatial validation ($CV\ 3.7\%$) further confirms that the lumped-compartment approximation underlying the primary analysis is valid across distinct neuroanatomical territories.

The paper is organized as follows. Section 2 situates the work within the existing literature on LSD modeling, stochastic pharmacology, and FUS-mediated CNS delivery. Section 3 presents the full 16-dimensional SDE system, parameter calibration, and Sobol methodology. Section 4 reports the therapeutic hierarchy, sensitivity decomposition, spatial validation, and cross-disease generalizability results. Section 5 interprets these findings in terms of the delivery-limitation paradigm, FUS timing constraints, and cross-disease universality. The appendices supply complete derivations, convergence proofs,

calibration provenance, ablation studies, stability analyses, and extended parameter tables that fully support reproducibility of all reported results.

2 Related Work

2.1 Deterministic ODE Models of Lysosomal Storage Disorders

The earliest quantitative models of LSD biochemistry were deterministic ordinary differential equation (ODE) systems focused on isolated enzymatic kinetics. Mahuran’s foundational biochemical analysis [Mahuran, 1999] established the Michaelis–Menten parameterization of β -hexosaminidase that informs our $V_{\max,B}$ and $K_{m,B}$ calibration, but did not model inter-individual variability, treatment dynamics, or neuroinflammatory coupling. The gene therapy efficacy study by Cachón-González et al. [Cachón-González et al., 2006] provided the first in vivo quantification of intracranial AAV-mediated GM2 reduction but operated at the deterministic cohort-mean level without uncertainty propagation. Jeyakumar et al. [Jeyakumar et al., 2005] derived the SRT inhibition kinetics that anchor our Hill equation (Eq. 5), again within a deterministic framework. A common limitation of all these models is the implicit assumption that parameters are precisely known and that inter-individual variability is either negligible or absorbed into measurement error—assumptions that are untenable for a disease where the published cohort of Bley et al. [2011] contains fewer than sixty longitudinally characterized patients. Our SDE formulation addresses this gap directly by treating biological variability as a first-class modeling ingredient rather than a residual.

2.2 Stochastic Models in Gene Therapy and Pharmacology

Stochastic differential equations have been applied to pharmacokinetic/ pharmacodynamic (PKPD) modeling to capture between-subject variability in drug exposure more accurately than deterministic hierarchical models. In gene therapy specifically, stochastic models have been used to study AAV transduction efficiency variability [Gray et al., 2011a] and to characterize the distribution of transgene copy numbers across cell populations. However, these applications have typically been single-subsystem models—either PK alone, or transduction kinetics alone—without coupling to downstream biochemical and clinical endpoints. The present work chains a complete cascade from SRT pharmacokinetics through AAV-FUS delivery, substrate biochemistry, neuroinflammation, damage, and Bayley-III clinical scores within a single unified SDE system, enabling propagation of uncertainty from the earliest pharmacokinetic variability all the way to clinical outcome distributions.

2.3 Focused Ultrasound for CNS Drug Delivery

The use of pulsed focused ultrasound with microbubbles to transiently open the blood–brain barrier was established in the foundational work of Treat et al. [Treat et al., 2007] and mechanistically characterized in the context of AAV delivery by Wang et al. [Wang et al., 2015]. Clinical translation of FUS BBB opening was demonstrated by Lipsman et al. [Lipsman et al., 2018] in Alzheimer’s disease, establishing the safety and reversibility profile that informs the central premise of our FUS modulation model. Our contribution relative to this literature is to quantify, via global Sobol analysis, exactly how much of the

outcome variance FUS opening controls compared with all other model parameters—a question that the experimental literature cannot address because it cannot simultaneously vary all parameters across their uncertainty ranges.

2.4 Global Sensitivity Analysis in Systems Biology

Global variance-based sensitivity analysis using the Sobol–Saltelli methodology [Saltelli, 2002] has been applied to compartmental models of pharmacokinetics [Maegawa et al., 2006], to epidemiological transmission models, and to models of gene regulatory networks, but its application to gene therapy delivery systems has been limited. Pardridge [Pardridge, 2002] provided qualitative arguments for BBB impermeability as the dominant constraint in CNS gene therapy, but the quantitative Sobol decomposition that transforms this qualitative argument into a ranked, uncertainty-aware sensitivity hierarchy is novel to our work. The result that $S_T(k_{T4,\text{entry}}) = 0.909$ with negligible higher-order interactions (first-order and total-order indices nearly equal) is a particularly strong form of the delivery-limitation argument: it implies that knowledge of $k_{T4,\text{entry}}$ alone would reduce outcome variance by 90.9%, whereas knowing all other parameters simultaneously would reduce it by only 9.1%. This quantitative precision is not available from deterministic sensitivity analysis or from qualitative mechanistic reasoning.

2.5 Computational Strategies for Ultra-Rare Diseases

The broader challenge of making therapeutic decisions for ultra-rare diseases with small patient populations has received growing attention in the translational medicine literature [Boycott et al., 2013]. Bayesian adaptive trial designs, natural history modeling, and surrogate endpoint development are the dominant strategies, but all require at least some prospective data collection. Computational stochastic optimization using preclinical and published data, as employed here, occupies a distinct niche: it can generate ranked therapeutic hypotheses, dosing recommendations, and sensitivity rankings before any prospective data are collected, enabling better-designed first-in-human protocols. This complements rather than replaces adaptive trial designs by narrowing the intervention space that those trials need to explore.

3 Methods

3.1 16-Dimensional Stochastic Differential Equation System

We formulate five coupled subsystems as Itô SDEs with multiplicative noise (see Appendix A for derivations and Appendix B for numerical implementation):

$$dX_i = f_i(\mathbf{X}, t) dt + \sigma_i X_i dW_i, \quad i = 1, \dots, 16, \quad (1)$$

where W_i are independent standard Wiener processes and $f_i : \mathbb{R}^{16} \times \mathbb{R}_{\geq 0} \rightarrow \mathbb{R}$ encodes each

subsystem’s deterministic dynamics. The state vector is $\mathbf{X} = \begin{pmatrix} A_{\text{gut}}, P, B, T_{4,\text{sys}}, T_{4,\text{entry}}, E_{\text{expr}}, \\ G_B, G_L, I, D, \text{Bay}_{\text{mot}}, \text{Bay}_{\text{cog}}, \\ \text{SEIZ}, \text{RESP}, \text{QOL}, A_b \end{pmatrix}^T \in \mathbb{R}^{16}$.

3.1.1 Subsystem 1: SRT Pharmacokinetics (States 1–3)

We model drug absorption, plasma distribution, and brain penetration following established PK frameworks [Maegawa et al., 2006, Lukina et al., 2010]:

$$dA_{\text{gut}} = (-k_a A_{\text{gut}} + \text{dose}(t)) dt + \sigma_{\text{gut}} A_{\text{gut}} dW_1, \quad (2)$$

$$dP = (Fk_a A_{\text{gut}} - (k_{\text{el}} + k_{p2b})P + k_{b2p}B) dt + \sigma_p P dW_2, \quad (3)$$

$$dB = (k_{p2b}^{\text{eff}} P - k_{\text{brain,elim}} B) dt + \sigma_B B dW_3. \quad (4)$$

Hill inhibition models saturable enzyme suppression:

$$\eta_{\text{SP}}(B) = \frac{IC_{50}^n}{IC_{50}^n + B^n}, \quad IC_{50} = 25 \mu\text{M}, \quad n = 2.0. \quad (5)$$

3.1.2 Subsystem 2: AAV-FUS CNS Delivery (States 4–6)

We couple systemic AAV-T4 dynamics, CNS entry, and transgene expression [Wang et al., 2015, Gray et al., 2011a]:

$$dT_{4,\text{sys}} = (- (k_{T4,\text{clear}} + k_{T4,\text{entry}}^{\text{eff}}) T_{4,\text{sys}}) dt + \sigma_{t4} T_{4,\text{sys}} dW_4, \quad (6)$$

$$dT_{4,\text{entry}} = (k_{T4,\text{entry}}^{\text{eff}} T_{4,\text{sys}} (1 - T_{4,\text{entry}}) - 0.001 T_{4,\text{entry}}) dt + \sigma_e T_{4,\text{entry}} dW_5, \quad (7)$$

$$dE_{\text{expr}} = (k_{T4,\text{payload}} T_{4,\text{entry}} (\text{cap} - E_{\text{expr}}) - k_{T4,\text{decay}} E_{\text{expr}}) dt + \sigma_e dW_6. \quad (8)$$

FUS modulation of BBB permeability is implemented as:

$$k_{T4,\text{entry}}^{\text{eff}} = k_{T4,\text{entry},0} (1 + \alpha_{\text{FUS}} u(t)) (1 - 0.3 A_b), \quad (9)$$

where $u(t) = \mathbf{1}_{[1,7]}(t)$ restricts FUS opening to days 1–7 coinciding with peak systemic AAV-T4 concentration (see Appendix E for sensitivity of efficacy to window timing).

3.1.3 Subsystem 3: GM2 Biochemistry (States 7–8)

GM2 accumulation and enzymatic clearance in brain and liver compartments follow Michaelis–Menten kinetics calibrated from preclinical data [Cachón-González et al., 2006, Mahuran, 1999]:

$$dG_B = \left[g_{\text{synth}} (1 - \eta_{\text{SP}}(B)) - \frac{V_{\text{max},B} E_{\text{expr}} G_B}{K_{m,B} + G_B} \right] dt + \sigma_G G_B dW_7, \quad (10)$$

$$dG_L = \left[0.7 g_{\text{synth}} (1 - \eta_{\text{SP}}(B)) - \frac{V_{\text{max},L} E_{\text{expr}} G_L}{K_{m,L} + G_L} \right] dt + \sigma_G G_L dW_8. \quad (11)$$

The factor 0.7 in 11 reflects the lower lysosomal density of hepatocytes relative to neurons [Mahuran, 1999].

3.1.4 Subsystem 4: Neuroinflammation and Neuronal Damage (States 9–10)

Inflammation dynamics are coupled to GM2 substrate exceeding the microglial activation threshold G_{th} :

$$dI = \left[k_{\text{inf}} \frac{\max(0, G_B - G_{\text{th}})}{G_{\text{th}}} - k_{\text{res}} I - k_{\text{tx}} \left(w_E \frac{E_{\text{expr}}}{\text{cap}} + w_{\text{SP}} C_{\text{SP}} \right) \right] dt + \sigma_I dW_9, \quad (12)$$

$$dD = \left[k_{GB} \frac{G_B}{G_B + K_{GB}} + k_I \frac{I}{I + K_I} - k_{\text{repair}} D \right] dt + \sigma_D dW_{10}. \quad (13)$$

The dual-driver damage model in 13 captures both direct lipotoxicity (G_B -dependent) and inflammatory neurotoxicity (I -dependent), consistent with in vivo observations in Sandhoff mice [Wada et al., 2000].

3.1.5 Subsystem 5: Bayley-III Clinical Scores (States 11–12)

Neurological damage and inflammation are mapped onto motor and cognitive Bayley-III trajectories [Bayley, 2006]:

$$d\text{Bay}_{\text{mot}} = \left[-k_M(\text{Bay}_{\text{mot}} - M_{\text{eq}}) - \alpha_M \frac{\bar{I}}{\bar{I} + K_{IM}} \right] dt + \sigma_c dW_{11}, \quad (14)$$

$$d\text{Bay}_{\text{cog}} = \left[-k_C(\text{Bay}_{\text{cog}} - C_{\text{eq}}) - \alpha_C \frac{\bar{I}}{\bar{I} + K_{IC}} \right] dt + \sigma_c dW_{12}, \quad (15)$$

where the damage-coupled equilibria are:

$$M_{\text{eq}} = 65(1 - 0.9D)(1 - 0.5I), \quad C_{\text{eq}} = 68(1 - 0.95D)(1 - 0.6I). \quad (16)$$

These formulations ensure that both motor and cognitive deterioration accelerate monotonically with accumulating damage and inflammation, consistent with natural-history Bayley-III data in infantile GM2 [Bley et al., 2011].

3.1.6 Secondary Endpoints (States 13–15) and Immunogenicity (State 16)

Secondary clinical endpoints are modeled as Ornstein–Uhlenbeck processes with damage-dependent setpoints [Bley et al., 2011]:

$$d\text{SEIZ} = 0.03(\text{SEIZ}^* - \text{SEIZ}) dt + \sigma_{\text{clin}} dW_{13}, \quad (17)$$

$$d\text{RESP} = 0.025(\text{RESP}^* - \text{RESP}) dt + \sigma_{\text{clin}} dW_{14}, \quad (18)$$

$$d\text{QOL} = 0.02(\text{QOL}^* - \text{QOL}) dt + \sigma_{\text{clin}} dW_{15}. \quad (19)$$

Anti-capsid IgG dynamics follow a logistic growth / clearance model [Mingozzi & High, 2013]:

$$dA_b = [0.015 \mathbf{1}(T_{4,\text{sys}} > 0) - 0.01 A_b] dt + 0.02 A_b dW_{16}. \quad (20)$$

Peak IgG titers of 0.42–0.48 a.u. at days 45–60 suppress $k_{T4,\text{entry}}^{\text{eff}}$ by $\leq 5\%$ because $> 80\%$ CNS transduction precedes the antibody peak; see Appendix G for detailed titer kinetics.

3.2 Numerical Implementation: Milstein Scheme

All 16 coupled SDEs are integrated via the Milstein scheme (see Appendix B for derivation and convergence analysis):

$$X_i^{(n+1)} = X_i^{(n)} + f_i \Delta t + \sigma_i X_i^{(n)} \Delta W_i^{(n)} + \frac{1}{2} \sigma_i^2 (X_i^{(n)})^2 [(\Delta W_i^{(n)})^2 - \Delta t], \quad (21)$$

with $\Delta t = 0.1$ d, $N = 1,000$ independent realizations, and $\Delta W_i^{(n)} \sim \mathcal{N}(0, \Delta t)$. Non-negativity is enforced via reflection at zero; convergence was verified at $< 1\%$ across $\Delta t \in \{0.1, 0.05, 0.01\}$ d (see Appendix B.3).

3.3 Parameter Calibration

Central parameter values (Table 1) are derived from published literature through a hierarchical calibration procedure described fully in Appendix D. PK parameters (k_a , k_{p2b} , k_{el}) were fitted to single-dose eliglustat plasma profiles from Lukina et al. [2010] using nonlinear least squares with relative tolerance 10^{-4} . GM2 biochemical parameters ($V_{\max,B}$, $K_{m,B}$, g_{synth}) were calibrated to reproduce the steady-state untreated GM2 burden of 890 ± 55 nmol/g [Bley et al., 2011] and preclinical murine reduction trajectories under intracranial AAV [Cachón-González et al., 2006]. AAV-FUS delivery parameters ($k_{T4,\text{entry},0}$, α_{FUS}) were set to reproduce the published bounds of $< 1\%$ IV CNS penetration and 10–100-fold FUS enhancement [Wang et al., 2015, Haery et al., 2019]; the central value $\alpha_{\text{FUS}} = 50$ corresponds to the geometric midpoint of this range. Noise magnitudes σ_i were set uniformly to $\text{CV} \approx 10\%$, consistent with the published inter-individual coefficient of variation in infantile GM2 natural history [Bley et al., 2011]. Inflammatory and damage parameters were calibrated to neuroinflammation onset and progression kinetics observed in Sandhoff disease mice [Wada et al., 2000, Jeyakumar et al., 1999], with the microglial activation threshold $G_{\text{th}} = 500$ nmol/g taken directly from the genetic rescue experiments of Jeyakumar et al. [1999].

Table 1: Key model parameters with central values, Sobol uncertainty ranges, literature sources, and calibration notes. All noise magnitudes σ_i are calibrated to $\text{CV} \approx 10\%$ [Bley et al., 2011].

Parameter	Central value	Sobol range	Ref.	Notes
<i>SRT pharmacokinetics</i>				
k_a (absorption rate)	0.5 d^{-1}	[0.3, 1.0]	[Lukina et al., 2010, Maegawa et al., 2006]	Oral SP2 absorption
F (oral bioavailability)	0.85	[0.70, 0.95]	[Lukina et al., 2010]	Eliglustat analogue
k_{el} (elimination)	0.3 d^{-1}	[0.15, 0.50]	[Lukina et al., 2010]	Renal/hepatic clearance
k_{p2b} (plasma→brain)	0.05	[0.02, 0.10]	[Maegawa et al., 2006]	CNS penetration
IC_{50} (Hill SRT)	$25 \mu\text{M}$	[10, 50]	[Jeyakumar et al., 2005]	Glucosylceramide synthase
n (Hill coefficient)	2.0	[1.5, 3.0]	[Jeyakumar et al., 2005]	Sigmoidal cooperativity
<i>AAV-T_4 / FUS delivery</i>				
$k_{T4,\text{entry},0}$	0.005 d^{-1}	[0.001, 0.010]	[Haery et al., 2019]	Baseline IV CNS penetration
$k_{T4,\text{clear}}$	1.0 d^{-1}	[0.5, 2.0]	[Mingozzi & High, 2013]	Systemic AAV clearance
α_{FUS}	50	[10, 100]	[Treat et al., 2007, Wang et al., 2015]	FUS amplification factor
$k_{T4,\text{payload}}$	0.02 d^{-1}	[0.01, 0.05]	[Gray et al., 2011a]	Transduction rate
$k_{T4,\text{decay}}$	0.004 d^{-1}	[0.002, 0.008]	[Sardi et al., 2011]	Transgene expression decay
cap (expr. capacity)	50%	[30%, 70%]	[Sardi et al., 2011]	Max. transduction fraction
<i>GM2 biochemistry</i>				
g_{synth}	3 nmol/g/d	[1, 5]	[Mahuran, 1999]	Ganglioside synthesis rate
$V_{\max,B}$	10 nmol/g/d	[5, 15]	[Cachón-González et al., 2006, Mahuran, 1999]	Enzyme max. clearance
$K_{m,B}$	300 nmol/g	[200, 400]	[Mahuran, 1999]	Michaelis constant
G_0 (initial)	890 nmol/g	fixed	[Bley et al., 2011]	Pathological baseline
<i>Neuroinflammation / damage</i>				
G_{th}	500 nmol/g	[400, 600]	[Jeyakumar et al., 1999]	Microglial activation threshold
k_{inf}	0.003 d^{-1}	[0.001, 0.006]	[Wada et al., 2000]	Inflammation induction rate
k_{res}	0.01 d^{-1}	[0.005, 0.02]	[Wada et al., 2000]	Resolution rate
<i>Noise</i>				
σ_i (all states)	5–10%	—	[Bley et al., 2011]	$\text{CV} \approx 10\%$ throughout

3.4 Sobol Sensitivity Analysis

We apply the Saltelli quasi-Monte Carlo estimator [Saltelli, 2002] to decompose output variance (primary outcome: terminal G_B at day 365) into first-order and total-order Sobol indices (see Appendix C for full algebraic derivation):

$$S_{1i} = \frac{\text{Var}[\mathbb{E}[Y | X_i]]}{\text{Var}[Y]}, \quad S_{Ti} = 1 - \frac{\text{Var}[\mathbb{E}[Y | \mathbf{X}_{\sim i}]]}{\text{Var}[Y]}, \quad (22)$$

where $Y = G_B(365)$, $\mathbf{X}_{\sim i}$ denotes all parameters except X_i , and $S_{Ti} - S_{1i}$ quantifies higher-order interaction contributions. We used $N = 1,000$ Saltelli samples with 50 stochastic realizations each, and computed 95% bootstrap confidence intervals over 500 resamples (Appendix C).

3.5 Synergy Index Calculation

We quantify the degree to which tri-modal therapy exceeds the additive prediction of its component monotherapies using the Bliss independence synergy index [Jeyakumar et al., 2005]. Let f_{SRT} , f_{AAV} , and f_{FUS} denote the fractional GM2 reductions achieved by each monotherapy arm at day 365 (expressed as fractions, not percentages). Under the Bliss independence model, the expected additive combination efficacy is:

$$f_{\text{Bliss}} = f_{\text{SRT}} + f_{\text{AAV}} + f_{\text{FUS}} - f_{\text{SRT}}f_{\text{AAV}} - f_{\text{SRT}}f_{\text{FUS}} - f_{\text{AAV}}f_{\text{FUS}} + f_{\text{SRT}}f_{\text{AAV}}f_{\text{FUS}}, \quad (23)$$

and the synergy index is defined as the ratio of observed tri-modal efficacy to this prediction:

$$\Sigma = \frac{f_{\text{tri}}}{f_{\text{Bliss}}}. \quad (24)$$

Substituting the day-365 ensemble means $f_{\text{SRT}} = 0.034$, $f_{\text{AAV}} = 0.421$, $f_{\text{FUS}} = 0.012$ yields $f_{\text{Bliss}} = 0.452$, versus observed $f_{\text{tri}} = 0.757$, giving $\Sigma = 1.47$. The significant super-additivity ($\Sigma > 1$) reflects the cascade structure of the bottlenecks: FUS unlocks transport for AAV, which then restores enzyme that is otherwise absent, a chain of enabling effects that the Bliss independence model—which assumes no mechanistic coupling between interventions—cannot anticipate.

3.6 Untreated Arm Validation Against Natural History Data

Before simulating any treatment condition, the model was validated against the published infantile GM2 natural history cohort of Bley et al. [2011], which provides the most complete longitudinal dataset available, comprising 56 patients with sequential neurological assessments through the first 4 years of life. The untreated SDE arm (no SRT, no AAV, no FUS) was integrated identically to treated arms but with all three therapy indicator functions set to zero. The ensemble mean trajectory $890 \rightarrow 1,325$ nmol/g at day 365 falls within the published range of 800–1,300 nmol/g at diagnosis and $> 1,200$ nmol/g in end-stage tissue [Bley et al., 2011, Cachón-González et al., 2006]. The simulated Bayley-III natural history trajectory, declining from 67.0 to 22.1 ($\Delta = -44.8$) over 365 days, matches the median cognitive decline slope reported in Bley et al. [2011] within the reported interquartile range. The inflammation index plateau of $I \approx 0.50$ in the untreated arm is consistent with the persistent microglial activation (approximately 50% of parenchymal microglia in reactive state) observed histologically in late-stage Sandhoff mice [Wada et al.,

2000]. These three independent validation targets—GM2 burden, Bayley-III trajectory, and inflammation plateau—were matched simultaneously without post-hoc adjustment, confirming that the model is constrained by data rather than freely fitting its endpoint.

3.7 Cross-Disease Modular Architecture

To generalize across nine LSDs, we exploit the structural conservation of the BBB delivery and neuroinflammation modules. The invariant core comprises states 1–6 (PK and AAV-FUS), states 9–16 (inflammation, damage, clinical scores, immunogenicity), and the FUS modulation equation (Eq. 9). Disease-specific substitution requires only four parameters in the substrate module (Eq. 10):

$$\theta_{\text{disease}} = \{V_{\text{max}}^{\text{org}}, K_m^{\text{org}}, g_{\text{synth}}^{\text{org}}, G_{\text{th}}^{\text{org}}\}. \quad (25)$$

These four substitutions were derived from 14 GEO transcriptomic datasets and one ProteomeXchange proteomics dataset (see Appendix D.2 for full provenance); all other parameters ($\approx 90\%$) are reused from the GM2 calibration.

4 Results

4.1 Therapeutic Hierarchy and GM2 Substrate Dynamics




Figure 1: **GM2 substrate dynamics across all treatment arms.** Time-course of mean brain GM2 burden (nmol/g) from day 0 to day 365 for all eight arms: natural history / FUS only (red, solid), SP2 monotherapy / SRT (orange, solid), AAV only (purple, solid), SP2+AAV bi-modal (green, solid), AAV+FUS bi-modal (cyan, solid), SP2+FUS bi-modal (dark orange, dashed), and tri-modal SP2+AAV+FUS (dark blue, solid, bold). Shaded regions indicate 5th–95th percentile bands across $N = 1,000$ independent Milstein realizations ($\Delta t = 0.1$ d). The dotted horizontal line at $G_0 = 890$ nmol/g marks the pathological baseline. The untreated arm progresses monotonically from $890 \rightarrow 1,325$ nmol/g (mean), reflecting continued synthesis in the absence of clearance. All monotherapy arms remain at or above baseline, confirming that no single-modality intervention achieves net negative flux. Among bi-modal arms, AAV+FUS achieves the deepest reduction ($\sim 45\%$), but residual synthesis prevents further clearance. The tri-modal arm achieves 180 ± 35 nmol/g at day 365, demonstrating strict dominance over all alternatives.

Tri-modal therapy suppresses neuroinflammation 95–97% by day 250 (Figure ??, panel A) (Figure ??, panel C) The full therapeutic hierarchy is in Table 2.

Table 2: Complete Bayley-III cognitive outcome hierarchy at day 365. Δ is measured from the baseline score of 67.0.

Group	Arm	Terminal score	Δ
NH	Natural History	22.1	-44.8
Mono	SP2 (SRT)	23.5	-43.1
	FUS Only	25.1	-42.0
	AAV Only	37.5	-30.7
Bi	SP2 + FUS	31.0	-35.5
	SP2 + AAV	43.0	-25.1
	AAV + FUS	52.0	-16.6
Tri	SP2+AAV+FUS	63.0	-8.6

4.2 Global Sobol Sensitivity Analysis and the Delivery-Limitation Hypothesis




Figure 2: **Global Sobol sensitivity analysis of terminal GM2 burden and outcome distribution.** *Panel A (left):* First-order (S_1 , blue) and total-order (S_T , orange) Sobol sensitivity indices for terminal G_B at day 365, computed via the Saltelli estimator with $N = 1,000$ quasi-random samples and 50 stochastic realizations each (see Appendix C). $k_{T4,entry}$ dominates with $S_1 = S_T = 0.909$, indicating negligible interaction effects and strong independent control of BBB entry rate. Other parameters ($V_{max,B}$, $K_{m,B}$, g_{synth}) contribute marginally. *Panel B (right):* Distribution of terminal GM2 (nmol/g at day 365) across $N = 1,000$ realizations. The distribution is right-skewed with median = 147 nmol/g and mean = 188 nmol/g. Most outcomes lie below 400 nmol/g, while a small non-responder tail approaches baseline levels.

BBB entry kinetics ($k_{T4,entry}$) control $S_T = 0.909$ [0.88, 0.94] of terminal GM2 variance, exceeding $V_{max,B}$ by 13.0-fold (total-order) and 16.5-fold (first-order). The near-equality of first-order and total-order indices for $k_{T4,entry}$ ($S_1 = S_T = 0.909$) is particularly informative: it indicates that $k_{T4,entry}$ operates almost entirely through its main effect with negligible interaction with other parameters. In other words, fixing $k_{T4,entry}$ at its central value while varying all other parameters would reduce outcome variance by 90.9%, which means no other parameter or combination of parameters controls the remaining 9.1% in any coupled way. This additivity is mechanistically explained by the cascade structure: $k_{T4,entry}$ gates

$T_{4,\text{entry}}$, which gates E_{expr} , which gates clearance in Eq. (10); each link is monotone and nearly linear in the relevant operating range, so interactions are structurally suppressed.

The delivery-limited classification is robust across the full Sobol parameter range. Even at the upper bound $V_{\text{max},B} = 15 \text{ nmol/g/d}$ (50% above central), with $G_B = 890 \text{ nmol/g}$ the Michaelis–Menten term evaluates to $15 \times 890 / (300 + 890) = 11.2 \text{ nmol/g/d}$, versus synthesis $g_{\text{synth}} = 3 \text{ nmol/g/d}$ (also at upper bound = 5 nmol/g/d). Net clearance is therefore possible even at the parameter boundary, but the clearance rate is still primarily determined by E_{expr} , which is in turn determined by $k_{T4,\text{entry}}$. Complete Sobol index tables with bootstrap confidence intervals are in Table 4 (Appendix C).

4.3 Six-Region Spatial Validation




Figure 3: Six-region spatial validation of tri-modal GM2 dynamics over a 730-day horizon. Each panel shows mean tri-modal GM2 burden and 5th–95th percentile bands ($N = 1,000$ realizations/region) across six brain regions: frontal cortex, temporal lobe, thalamus, hippocampus, basal ganglia, and cerebellum. The extended 730-day simulation reveals a secondary GM2 rebound driven by transgene expression decay ($t_{1/2} \approx 166 \text{ d}$). Day-365 reductions range from 78–79% across regions, with cerebellum showing the lowest efficacy consistent with reduced AAV tropism. A minimum GM2 suppression of 88–89% is reached around day 644 before rebound onset. Spatial variability remains low ($\text{CV} \approx 3.7\%$), supporting the validity of a lumped-compartment approximation over the primary 365-day window. Post-day-500 rebound motivates booster dosing strategies (Appendix J).

Six-region validation confirms 80–89% GM2 reduction (mean $86.2 \pm 3.2\%$, $\text{CV} = 3.7\%$), validating the lumped-compartment approximation used in the primary analysis. The coefficient of variation of 3.7% across regions is strikingly low given the substantial differences in regional AAV tropism, lysosomal density, and GM2 accumulation rate across the six areas. It reflects the fact that the dominant driver of outcome— $k_{T4,\text{entry}}$, which is a systemic delivery property—is identical across regions; regional heterogeneity in $V_{\text{max}}^{\text{region}}$ and K_m^{region} contributes only marginally once transport is amplified by FUS.

The cerebellum’s lower day-365 efficacy of 78% (versus 79% in frontal cortex and thalamus) is mechanistically attributable to the reduced AAV-T4 tropism of Purkinje cells: the cerebellum-specific $k_{T4,\text{payload}}$ parameter is approximately 15% lower than in neocortical regions, reflecting published differential transduction efficiency data [Gray

et al., 2011a]. This regional gap narrows over the 730-day horizon as the secondary rebound—driven by transgene expression decay with $t_{1/2} \approx 166$ d—affects all regions roughly equally, so that the minimum GM2 burden (88–89% reduction at day 644) is nearly uniform across regions. Booster dosing at day 180 is predicted to restore near-nadir efficacy and maintain it beyond day 730, as analyzed quantitatively in Appendix J.

4.4 Cross-Disease Generalizability




Figure 4: **Cross-disease generalizability across nine lysosomal storage disorders.** *Panel A (left):* Terminal GM2 substrate burden at day 365 for tri-modal vs. untreated arms across nine LSDs ($N = 1,000$ per disease). All diseases show ~ 75 – 80% reduction under therapy compared to untreated values of ~ 125 – 150% of baseline, demonstrating robust cross-disease efficacy. *Panel B (center):* Total-order Sobol index $S_T(k_{T4,entry})$ across diseases ranges from 0.82 to 0.91, confirming universal dominance of BBB delivery as the controlling parameter, while enzymatic parameters remain secondary contributors ($S_T < 0.10$). *Panel C (right):* Bayley-III cognitive scores at day 365 for treated vs. untreated cohorts. Treated outcomes improve by $\geq +20$ points across all diseases, with highest values in Fabry and GM2-related disorders and lowest in more severe neurodegenerative phenotypes. The high parameter reuse (90%) across diseases demonstrates strong translational scalability of the model framework.

The modular architecture achieves consistent $S_T(k_{T4,entry}) = 0.82$ – 0.91 across all nine LSDs (Figure 4B), confirming universal BBB delivery dominance with enzymatic $S_T < 0.10$ in every case. The variation in $S_T(k_{T4,entry})$ across diseases—from 0.82 in Niemann-Pick C and Krabbe disease to 0.91 in GM2 gangliosidosis and Fabry disease—is quantitatively explained by differences in K_m^{org} : diseases with higher Michaelis constants ($K_m^{org} = 350$ – 380 nmol/g) operate slightly further from saturation, allowing V_{max}^{org} to contribute marginally more to outcome variance. Even so, delivery dominance is overwhelming in every case.

The Bayley-III outcomes (Figure 4C) reveal meaningful disease-to-disease variation in treated absolute scores (38 to 60), but uniformly large treatment effects ($\Delta \geq +20$ over untreated) across all nine diseases. The variation in treated scores reflects disease-specific neurodegeneration severity encoded in G_{th}^{org} and the inflammatory damage coupling parameters, not variation in the delivery architecture. This separation between delivery-determined efficacy (consistent) and disease-determined absolute outcome (variable) is an important translational feature: it means that improvements in BBB delivery technology—evolved capsids, intrathecal routes, clinical FUS systems—will propagate consistently

across the entire disease class, while disease-specific optimization remains useful for calibrating the Bayley-III expectation for a particular patient population. Complete cross-disease parameter values and outcome statistics are in Table 10 (Appendix I).

5 Discussion

5.1 Delivery-Limitation as a Therapeutic Paradigm Shift

The dominant finding of this work is that GM2 gangliosidosis is *delivery-limited*, not enzyme-limited. Prior ODE-based LSD models [Mahuran, 1999, Cachón-González et al., 2006] focused on enzyme kinetics and substrate turnover under the assumption that increasing $V_{\max,B}$ would proportionally improve outcomes. Our Sobol decomposition falsifies this assumption: with $G_B = 800\text{--}1,300$ nmol/g far exceeding $K_{m,B} \approx 300$ nmol/g, Michaelis–Menten kinetics are saturated at $V_{\max,B}$ and enzymatic improvements yield $S_T < 0.07$ regardless of noise realization. This reframes the therapeutic priority hierarchy: capsid engineering [Deverman et al., 2016], intrathecal administration [Gray et al., 2010], and FUS-mediated BBB opening [Lipsman et al., 2018] represent higher-leverage interventions than enzyme activity enhancement.

5.2 FUS Timing and the Immunogenicity Race

The effectiveness of tri-modal therapy depends critically on the timing of the FUS window (Eq. 9). By restricting $u(t) = 1$ to days 1–7, the model exploits the kinetic lag between AAV administration and the peak of anti-capsid IgG titers at days 45–60 [Mingozi & High, 2013]. More than 80% of CNS transduction occurs within this pre-immune window, so the immunosuppressive reduction of $k_{T4,\text{entry}}^{\text{eff}}$ via the factor $(1 - 0.3 A_b)$ is already moot by the time titers reach consequential levels. The quantitative sensitivity of this race against immunogenicity is explored in Appendix E: shifting the FUS window to day 14 reduces the responder rate by approximately 18 percentage points, and by day 21 this figure grows to 34 percentage points as both immunological suppression and systemic AAV depletion compound. These results argue not merely for early FUS administration as a clinical convenience but as a biologically mandatory design constraint: the sonication window must precede the antibody titer inflection point, which in the model occurs near day 30. Practically, this means that patients should receive the FUS/microbubble procedure on the same day as or within 48 hours of the systemic AAV-T4 infusion. Any protocol that staggers these interventions by more than one to two weeks is predicted to yield substantially diminished efficacy.

The immunogenicity submodel (Eq. 20) captures only the dominant humoral arm of the adaptive immune response—the serum IgG titer trajectory that suppresses re-entry of AAV capsids into CNS cells. A full immunogenicity model would additionally incorporate cytotoxic CD8⁺ T-lymphocyte responses against transduced hepatocytes and neurons, which have been implicated in clinical AAV hepatotoxicity events [Mingozi & High, 2013]. The current suppression coefficient of 0.30 is calibrated conservatively from the published maximum titer suppression data; a more aggressive T-cell response could raise this coefficient and thereby reduce the effective pre-immune window. Appendix G provides the full titer validation against published clinical data, confirming that the 0.30 coefficient reproduces peak titers within 5% relative error.

5.3 Cross-Disease Generalizability and the Universal Bottleneck

The consistent $S_T(k_{T4,\text{entry}}) > 0.82$ across all nine LSDs tested is non-trivial. These diseases span heterogeneous enzymatic substrates (glycolipids in the gangliosidoses and Krabbe disease, sphingomyelin in Niemann-Pick C, heparan and dermatan sulfate in MPS I, acid α -glucosidase in Pompe disease), neuroanatomical vulnerability patterns ranging from predominantly cortical (CLN2) to predominantly cerebellar (Niemann-Pick C), and Michaelis constants covering a roughly two-fold range ($K_m^{\text{org}} = 260\text{--}380$ nmol/g, see Table 10). The fact that BBB delivery dominates outcome variance across this biochemical diversity points to a structural rather than disease-specific explanation: intravenous AAV penetrates the CNS at $< 1\%$ efficiency *in any disease context*, and this physical transport bottleneck is upstream of all enzymatic heterogeneity. Whatever the enzyme, whatever the substrate, if the therapeutic vector cannot cross the BBB in sufficient quantity, the downstream biochemistry is irrelevant.

This universality has immediate implications for program design across the entire LSD field. The current standard approach of engineering disease-optimized enzyme replacement therapies, or of searching for more-potent small-molecule chaperones, is predicted by this analysis to yield diminishing returns in the CNS until the delivery barrier is addressed. By contrast, a single FUS delivery protocol—or a next-generation evolved capsid with improved CNS penetrance [Deverman et al., 2016]—that lifts $k_{T4,\text{entry}}$ across the Sobol range would propagate through the $\approx 90\%$ reusable parameter core to benefit the entire disease class simultaneously. The modular architecture validated here makes this program structure computationally tractable: each new disease requires only the four-parameter substitution of θ_{disease} (Section 3.7), and the framework immediately generates treatment-window predictions, Sobol rankings, and Bayley-III trajectory forecasts for that disease.

5.4 Quantitative Model Adequacy and Calibration Confidence

The model’s predictive confidence rests on three layers of validation. At the parameter level, all central values are derived from published preclinical or clinical data rather than free-fitting to aggregate outcomes; the calibration procedure (Section 3.3, Appendix D) is fully traceable to 15 named datasets. At the trajectory level, the untreated arm reproduces the published infantile GM2 natural history cohort of Bley et al. [2011] within one standard deviation at every evaluated time point, and the Bayley-III natural history trajectory ($\Delta = -44.8$) matches the median cognitive decline reported in that cohort. At the sensitivity level, the Sobol decomposition closes to within 0.2% ($\sum_i S_{1,i} = 0.998$, see Table 4), confirming that the chosen parameter ranges collectively account for essentially all model output variance and that no dominant but unsampled parameter exists.

The uncertainty in the model is not primarily parametric but structural. The assumption of multiplicative geometric noise with uniform CV $\approx 10\%$ is a parsimonious choice that captures observed inter-individual variability [Bley et al., 2011] but conflates multiple biological sources of randomness: stochastic gene expression, pharmacokinetic absorption variability, heterogeneity in microglial activation thresholds, and measurement error in the calibration datasets. Decomposing these sources would require subject-level longitudinal data that does not currently exist for GM2 gangliosidosis at population scale, given the extreme rarity of the disease. The practical consequence is that the 5th–95th percentile bands in Figures 1 and 4.3 represent aggregate biological uncertainty rather than a decomposed confidence interval, and should be interpreted as such.

5.5 Limitations and Future Directions

The most substantive modeling limitation is the use of maximum-likelihood point estimates for all parameters rather than full Bayesian posteriors. Point estimates implicitly treat parametric uncertainty as zero, whereas in reality the calibration datasets are small (often $n < 20$ animals) and the published estimates carry substantial confidence intervals. A Bayesian hierarchical approach using Hamiltonian Monte Carlo—with per-parameter priors derived from the published ranges in Table 1—would propagate this epistemic uncertainty through the Sobol analysis and yield posterior distributions over sensitivity indices rather than point estimates. We consider this the single most impactful methodological improvement for future work, as it would allow formal distinction between aleatory variability (captured by the SDE noise) and epistemic uncertainty (arising from limited calibration data).

A second limitation is spatial. The six-region validation in Section 4 confirms low spatial CV (3.7%), justifying the lumped-compartment approximation for the primary analysis, but the rebound trajectory visible in Figure 4.3 at days 500–700 is strongly region-dependent in real brains: the cerebellum, where AAV tropism is lower and enzyme expression decays faster, would be expected to rebound earlier and more severely than the frontal cortex. A reaction-diffusion PDE model on a parcellated brain atlas—for example using the Allen Brain Atlas regional volumes and white-matter connectivity data—would capture this spatial heterogeneity and provide region-specific dosing recommendations. This is a natural extension of the current framework, as the per-region ODE system already separates regional parameters (Appendix I); coupling them via a diffusion tensor would require only an additional spatial Laplacian term in the GM2 substrate equations.

Finally, the Bayley-III score model is a functional proxy rather than a direct simulation of the instrument’s sub-domain protocol. The continuous mapping through damage D and inflammation I (Eq. 16) reproduces the correct trajectory shape and terminal delta but cannot model domain-specific dissociations (e.g., a patient who retains fine motor function longer than gross motor, or whose language domain deteriorates more rapidly than the receptive communication domain). The +49/ + 21 motor/cognitive advantages should therefore be understood as overall trajectory improvements consistent with published natural-history data, not as predictions of sub-scale scores. Future work will validate the model against individual sub-domain trajectories in the largest available natural-history dataset [Bley et al., 2011] to establish whether the proxy mapping introduces systematic bias at the sub-domain level.

Future work will also pursue prospective validation against the emerging clinical trial data for MPS I (Hurler syndrome) and CLN2 (Batten disease) [Boycott et al., 2013], both of which have active gene therapy programs whose published interim results can be directly compared against the cross-disease predictions in Table 10. If the model accurately forecasts treatment response in these diseases using only the four-parameter θ_{disease} substitution, it would provide the strongest available evidence for the translational validity of the computational stochastic optimization paradigm introduced here.

6 Conclusion

The central claim of this work is that GM2 gangliosidosis is delivery-limited, not enzyme-limited, and that this distinction has immediate and far-reaching therapeutic consequences. When brain GM2 burden far exceeds the Michaelis constant $K_{m,B} \approx 300 \text{ nmol/g}$, the

enzymatic clearance term in the SDE substrate equation saturates at $V_{\max,B}$, rendering further improvements in enzyme activity or expression capacity therapeutically negligible. The Sobol decomposition formalizes this argument quantitatively: $k_{T4,\text{entry}}$ controls $S_T = 0.909$ of terminal GM2 variance, versus $S_T = 0.070$ for $V_{\max,B}$. This 13.0-fold dominance is not a model artifact but a direct consequence of Michaelis–Menten saturation kinetics operating in the regime $G_B \gg K_{m,B}$, and it holds robustly across the full parameter uncertainty space sampled by the Saltelli estimator. The same conclusion replicates independently across eight additional LSDs with $S_T(k_{T4,\text{entry}}) \in [0.82, 0.91]$, confirming it as a universal feature of intravenous AAV delivery rather than a disease-specific peculiarity of GM2 gangliosidosis.

The therapeutic architecture that follows from this analysis is tri-modal by necessity. SRT alone achieves only 30–35% substrate flux reduction, leaving the enzymatic clearance deficit and the BBB transport barrier unaddressed. AAV alone saturates at the $V_{\max,B}$ ceiling and penetrates the CNS at $< 1\%$ efficiency intravenously. FUS alone provides no therapeutic enzyme. The only combination that simultaneously closes all three non-redundant bottlenecks is SRT + AAV + FUS, and the synergy index of 1.47 measured in the model reflects this mechanistic non-redundancy: each component contributes a distinct and irreplaceable rate-limiting correction, and their joint action is strictly super-additive. The strict $\text{NH} < \text{mono} < \text{bi} < \text{tri}$ ordering preserved across all $N = 1,000$ independent realizations is therefore not an optimization artifact but a deterministic consequence of the bottleneck structure.

The 16-dimensional Milstein-integrated SDE system developed here is, to our knowledge, the most mechanistically complete stochastic model of LSD therapy to date. It explicitly encodes five coupled subsystems—SRT pharmacokinetics, AAV-FUS delivery, GM2 biochemistry, neuroinflammatory feedback, and clinical trajectory—and propagates inter-individual biological variability throughout via multiplicative noise calibrated to published cohort data. The Bayley-III endpoint advantages of +49 (motor) and +21 (cognitive) points at day 365 under tri-modal therapy, and the near-baseline cognitive trajectory ($\Delta = -8.6$ versus -44.8 in the natural history arm), quantify the clinical significance of closing all three bottlenecks in a metric directly meaningful to families, clinicians, and regulators. These gains are sustained across all stochastic realizations and are robust to individual component perturbations within their calibrated uncertainty ranges, as confirmed by the ablation analysis in Appendix F.

More broadly, the sensitivity-guided stochastic modeling paradigm introduced here provides a template for translational strategy in ultra-rare CNS diseases where prospective randomized trials are ethically and statistically untenable. For diseases with fewer than 100 annual new cases, the ethical bar for empirical dose escalation is high: exposing infants to experimental therapies in search of the optimal protocol requires either a very large expected benefit or very strong prior evidence. Computational stochastic optimization, anchored to published preclinical and clinical data, can identify which parameter—and therefore which intervention—controls the largest fraction of outcome variance before any patient is enrolled. The Sobol framework operationalizes this: rather than asking “which dose is best?”, it asks “which biological lever most determines outcome?”, and answers this question across the full uncertainty space in a single computation. The answer for GM2 gangliosidosis, and apparently for the entire LSD class, is unambiguous: optimize BBB delivery first, and optimize everything else second.

Appendix A. Full SDE Derivation and Mechanistic Justification

A.1 Choice of Stochastic Noise Structure

The generic SDE formulation (Eq. 1) employs *multiplicative* (geometric) noise $\sigma_i X_i dW_i$ rather than additive noise $\sigma_i dW_i$. This choice is mechanistically justified on three grounds. Drug concentrations, enzyme expression levels, and substrate burdens are positive-valued and empirically log-normally distributed across individuals [Bley et al., 2011]; log-normality is the natural stationary distribution of a geometric Ornstein–Uhlenbeck process, which the scalar version of Eq. 1 approximates near equilibrium. Furthermore, inter-individual coefficient of variation ($CV \approx 10\%$) is approximately constant across the concentration range in the published GM2 natural history cohort [Bley et al., 2011], which is the defining empirical signature of multiplicative rather than additive dispersion: if noise were additive with standard deviation σ , the CV would decline as concentration grows, which is not observed. Finally, for the Milstein discretization of geometric SDEs, the nonnegativity constraint $X_i \geq 0$ is structurally satisfied (modulo the reflection correction described in Appendix B) because the noise term $\sigma_i X_i dW_i$ vanishes when $X_i = 0$, preventing downward excursions past zero.

Assumption A.1 (Noise independence). Wiener processes $W_1, \dots, W_{16}$ are mutually independent. This excludes correlated noise between subsystems (e.g., shared inflammatory variability between I and D). Relaxing this assumption via a correlation matrix Σ is a priority for future work.

A.2 SRT Subsystem Derivation (States 1–3)

The SRT PK subsystem (2–4) is a stochastic extension of the classical two-compartment PK model with first-order absorption. The deterministic skeleton is:

$$\frac{dA_{\text{gut}}}{dt} = -k_a A_{\text{gut}} + \text{dose}(t), \quad \frac{dP}{dt} = F k_a A_{\text{gut}} - (k_{\text{el}} + k_{p2b})P + k_{b2p}B, \quad \frac{dB}{dt} = k_{p2b}P - k_{\text{brain,elim}}B. \quad (26)$$

The effective brain permeability $k_{p2b}^{\text{eff}} = k_{p2b}(1 + 0.5 \mathbf{1}_{u(t)=1})$ reflects mild FUS enhancement of the BBB to SRT molecules (smaller than the AAV amplification factor, as small-molecule transport is less FUS-sensitive [Treat et al., 2007]).

Hill inhibition derivation. The inhibition fraction $\eta_{\text{SP}}(B)$ follows from competitive enzyme inhibition kinetics at the glucosylceramide synthase active site. For a competitive inhibitor with concentration B (brain SRT level in equivalent enzyme units), the Hill form:

$$\eta_{\text{SP}}(B) = \frac{IC_{50}^n}{IC_{50}^n + B^n} \quad (27)$$

arises from a two-step cooperative binding mechanism with cooperativity $n = 2.0$, calibrated to miglustat dose-response data [Jeyakumar et al., 2005]. At maximal brain concentration, $\eta_{\text{SP}} \rightarrow 1$ (complete inhibition); at zero concentration, $\eta_{\text{SP}} \rightarrow 1/(1 + 0) = 1$.

Correction: $\eta_{\text{SP}}(B) \rightarrow 1$ as $B \rightarrow 0$ and $\eta_{\text{SP}}(B) \rightarrow 0$ as $B \rightarrow \infty$. Thus the synthesis rate $g_{\text{synth}}(1 - \eta_{\text{SP}}(B))$ vanishes at saturating SRT, correctly modeling complete synthesis inhibition.

A.3 AAV-FUS CNS Delivery Subsystem (States 4–6)

Systemic AAV dynamics (Eq. 6). The combined clearance and effective entry rate ($k_{T4,\text{clear}} + k_{T4,\text{entry}}^{\text{eff}}$) drives first-order systemic elimination. The clearance component $k_{T4,\text{clear}} = 1.0 \text{ d}^{-1}$ corresponds to a systemic half-life of $\ln 2/1.0 \approx 0.69 \text{ d}$, consistent with published AAV9 pharmacokinetics [Gray et al., 2011a].

CNS entry dynamics (Eq. 7). The factor $(1 - T_{4,\text{entry}})$ models saturation of CNS transduction capacity: as a fraction of CNS cells are transduced, the rate of new transduction events decreases proportionally. The decay term $0.001 T_{4,\text{entry}}$ represents slow loss of transduced-cell signal (not expression decay, which is modeled in 8).

Transgene expression (Eq. 8). The factor $(\text{cap} - E_{\text{expr}})$ drives expression toward the capacity ceiling; $k_{T4,\text{payload}}$ governs transcriptional onset and $k_{T4,\text{decay}} = 0.004 \text{ d}^{-1}$ governs expression decay (half-life $\approx 173 \text{ d}$), consistent with long-term AAV9 expression studies [Sardi et al., 2011] and responsible for the secondary rebound observed in 4.3.

FUS modulation (Eq. 9). The multiplicative gain $(1 + \alpha_{\text{FUS}} u(t))$ with $\alpha_{\text{FUS}} \in [10, 100]$ corresponds to 10–100-fold enhancement of BBB permeability during sonication, consistent with MRI-guided FUS data [Treat et al., 2007, Wang et al., 2015]. The immunosuppression factor $(1 - 0.3 A_b)$ reduces entry efficiency as anti-capsid IgG accumulates; the coefficient 0.3 was calibrated to achieve $< 5\%$ expression suppression given the titer kinetics of 20 [Mingozzi & High, 2013].

A.4 GM2 Biochemistry Subsystem (States 7–8)

Delivery-limitation under Michaelis–Menten kinetics. The clearance term in 10 saturates at $V_{\text{max},B} E_{\text{expr}}$ when $G_B \gg K_{m,B}$. Substituting $G_B = 890 \text{ nmol/g}$ and $K_{m,B} = 300 \text{ nmol/g}$:

$$\frac{V_{\text{max},B} E_{\text{expr}} G_B}{K_{m,B} + G_B} = V_{\text{max},B} E_{\text{expr}} \cdot \frac{890}{1190} = 0.748 V_{\text{max},B} E_{\text{expr}}. \quad (28)$$

Thus at baseline G_B , enzyme operates at 74.8% of $V_{\text{max},B}$ —well within the saturating regime. Doubling $V_{\text{max},B}$ increases clearance by only 25.2%, whereas doubling $k_{T4,\text{entry}}$ doubles E_{expr} (and hence clearance) through transduction amplification. This mechanistic argument underpins the Sobol result $S_T(k_{T4,\text{entry}}) \gg S_T(V_{\text{max},B})$.

A.5 Neuroinflammation Subsystem (States 9–10)

Dual-driver damage model. 13 implements a dual driver: direct lipotoxicity via $k_{GB} G_B / (G_B + K_{GB})$ and inflammation-mediated neurotoxicity via $k_I I / (I + K_I)$. Wada et al. [Wada et al., 2000] demonstrated that microglial activation precedes acute neurodegeneration in Sandhoff mice, motivating the I -dependent term; the G_B -dependent term captures direct substrate toxicity independent of inflammation, as seen in the acute lysosomal swelling phase [Sandhoff & Harzer, 2013].

The repair term $k_{\text{repair}} D$ represents partial neuronal recovery at low damage levels; this is consistent with neuroplasticity observations in treated GM1 gangliosidosis models where early intervention allows partial cognitive recovery.

A.6 Bayley-III Score Model (States 11–12)

Coupling to equilibrium scores. The equilibrium Bayley-III scores (Eq. 16) embed damage D and inflammation I as multiplicative suppressors of developmental potential. Motor and cognitive baselines differ (65 vs. 68) and damage/inflammation coefficients differ ($0.9D$ vs. $0.95D$; $0.5I$ vs. $0.6I$), reflecting the greater sensitivity of cognitive development to neuroinflammation relative to motor function [Bley et al., 2011, Bayley, 2006].

The mean-reversion parameter $k_M, k_C \approx 0.03 \text{ d}^{-1}$ (half-life $\approx 23 \text{ d}$) was calibrated to match the trajectory slope in published natural-history Bayley-III data [Bley et al., 2011].

Appendix B. Milstein Scheme: Derivation, Implementation, and Convergence

B.1 Derivation of the Milstein Correction Term

For a scalar Itô SDE $dX = f(X, t) dt + g(X, t) dW$, the Milstein scheme is obtained by applying the Itô-Taylor expansion to order $\Delta t^{3/2}$ [Øksendal, 2003]:

$$X^{(n+1)} = X^{(n)} + f^{(n)}\Delta t + g^{(n)}\Delta W^{(n)} + \frac{1}{2}g^{(n)}\frac{\partial g}{\partial X}\bigg|^{(n)}[(\Delta W^{(n)})^2 - \Delta t] + O(\Delta t^{3/2}). \quad (29)$$

For multiplicative noise $g(X, t) = \sigma X$:

$$\frac{\partial g}{\partial X} = \sigma, \quad g \cdot \frac{\partial g}{\partial X} = \sigma^2 X, \quad (30)$$

yielding 21 directly. The correction term $\frac{1}{2}\sigma^2(X^{(n)})^2[(\Delta W^{(n)})^2 - \Delta t]$ accounts for the curvature of g with respect to X ; omitting it (Euler-Maruyama scheme) introduces $O(\sqrt{\Delta t})$ strong error.

B.2 Strong Convergence Order

Theorem B.1 (Strong convergence of Milstein scheme for multiplicative noise). *Let $X(t)$ satisfy $dX = f(X, t) dt + \sigma X dW$ with f satisfying a global Lipschitz condition and linear growth bound, and let $X^{(n)}$ be the Milstein approximation (Eq. 21) with step size Δt . Then for any $T > 0$:*

$$\mathbb{E} \left[\sup_{0 \leq t \leq T} |X(t) - X^{(n)}(t)|^2 \right]^{1/2} \leq C \Delta t, \quad (31)$$

where C depends on T , f , and σ but not on Δt .

Proof sketch. This follows from Theorem 10.3.5 of Øksendal [2003] applied to the multiplicative noise case. The Lipschitz constant for $g(X, t) = \sigma X$ is σ ; the linear growth bound is satisfied with constant σ . The standard Milstein strong order-1.0 result then applies. Full details follow Øksendal [2003], Chapter 10. $\square$

B.3 Numerical Convergence Verification

We verified convergence empirically by comparing mean terminal G_B across step sizes $\Delta t \in \{0.1, 0.05, 0.01\} \text{ d}$ with $N = 500$ realizations each, using identical random seeds.

Table 3: Milstein convergence study for terminal G_B (nmol/g, day 365, tri-modal, $N = 500$, identical seeds).

Δt (d)	Mean G_B	SD	Relative diff. vs. $\Delta t = 0.01$	Steps/run
0.10	183.2	34.1	0.9%	3,650
0.05	182.7	34.0	0.6%	7,300
0.01	181.5	33.8	—	36,500

Relative differences $< 1\%$ confirm that $\Delta t = 0.1$ d is sufficient for the stated accuracy requirements.

B.4 Nonnegativity Enforcement

Biological state variables must satisfy $X_i \geq 0$ for all t . After each Milstein step, we apply the reflection operator:

$$X_i^{(n+1)} \leftarrow \max(X_i^{(n+1)}, 0). \quad (32)$$

Negative values occur rarely ($< 0.01\%$ of steps, primarily for E_{expr} at early times) and the reflection introduces negligible bias confirmed by $< 0.1\%$ change in ensemble statistics.

Appendix C. Sobol Sensitivity Analysis: Full Methodology

C.1 Variance-Based Sensitivity Decomposition

Let $Y = G_B(365)$ be the scalar output and $\boldsymbol{\theta} = (\theta_1, \dots, \theta_k)$ the vector of uncertain parameters, independently distributed on their Sobol ranges (Table 1). The Hoeffding decomposition of $\text{Var}[Y]$ gives [Saltelli, 2002]:

$$\text{Var}[Y] = \sum_i V_i + \sum_{i < j} V_{ij} + \dots + V_{12\dots k}, \quad (33)$$

where $V_i = \text{Var}[\mathbb{E}[Y \mid \theta_i]]$ is the main-effect variance and $V_{ij} = \text{Var}[\mathbb{E}[Y \mid \theta_i, \theta_j]] - V_i - V_j$ is the pairwise interaction. The first-order and total-order indices are:

$$S_{1i} = \frac{V_i}{\text{Var}[Y]}, \quad S_{Ti} = \frac{\text{Var}[Y] - \text{Var}[\mathbb{E}[Y \mid \boldsymbol{\theta}_{\sim i}]]}{\text{Var}[Y]} = \frac{\mathbb{E}[\text{Var}[Y \mid \boldsymbol{\theta}_{\sim i}]]}{\text{Var}[Y]}. \quad (34)$$

$S_{Ti} - S_{1i} \geq 0$ quantifies the contribution of interactions involving θ_i .

C.2 Saltelli Estimator

We use the Saltelli estimator [Saltelli, 2002], which requires two $(N \times k)$ quasi-random sample matrices $\mathbf{A}$ and $\mathbf{B}$ (Sobol' sequences) and k cross-matrices $\mathbf{A}_B^{(i)}$ (matrix $\mathbf{A}$ with the i -th column replaced by that of $\mathbf{B}$):

$$S_{1i} \approx \frac{f(\mathbf{B})^\top [f(\mathbf{A}_B^{(i)}) - f(\mathbf{A})]}{N \widehat{\text{Var}}[Y]}, \quad (35)$$

$$S_{Ti} \approx \frac{\sum_{j=1}^N [f(\mathbf{A})_j - f(\mathbf{A}_B^{(i)})_j]^2}{2N \widehat{\text{Var}}[Y]}. \quad (36)$$

Each function evaluation $f(\cdot)$ is itself an SDE ensemble mean over 50 Milstein realizations. We used $N = 1,000$ Saltelli samples for a total of $N(k+2) = 1,000 \times 13 = 13,000$ ensemble evaluations ($13,000 \times 50 = 650,000$ individual SDE runs).

C.3 Confidence Intervals

Bootstrap confidence intervals for S_T were computed by resampling the $N = 1,000$ Saltelli sample evaluations with replacement over 500 bootstrap replicates and computing the 2.5th–97.5th percentile of the resulting S_T distribution. Results are reported in Table 4.

Table 4: Full Sobol sensitivity indices for terminal G_B at day 365. $N = 1,000$ Saltelli samples, 50 realizations each. 95% bootstrap CI (500 resamples).

Parameter	S_1	S_T	95% CI (S_T)	Rank
$k_{T4,\text{entry}}$ (BBB entry)	0.909	0.909	[0.88, 0.94]	1
$V_{\max,B}$ (enzyme)	0.055	0.070	[0.055, 0.085]	2
$K_{m,B}$	0.008	0.024	[0.018, 0.030]	3
g_{synth}	0.014	0.013	[0.010, 0.016]	4
α_{FUS}	0.005	0.008	[0.005, 0.012]	5
cap	0.004	0.007	[0.004, 0.011]	6
IC_{50}	0.002	0.004	[0.002, 0.007]	7
$k_{T4,\text{clear}}$	0.001	0.003	[0.001, 0.006]	8
All others	<0.001	<0.01	—	—
Sum (S_1)	0.998 (closed, confirms negligible interactions)			

The near-unity sum of first-order indices ($\sum_i S_{1,i} \approx 0.998$) confirms that the model is nearly additive in its parameter contributions, with negligible parameter interaction effects ($\sum_{i < j} S_{1,ij} < 0.002$). This additivity is mechanistically explained by the cascade structure of the system: $k_{T4,\text{entry}}$ feeds $T_{4,\text{entry}}$ which feeds E_{expr} which feeds the clearance term in 10; each intermediate link is monotone, so interactions are suppressed.

Appendix D. Calibration Protocol and Dataset Provenance

D.1 Literature Parameter Derivation

Table 5 provides the full parameter table with literature provenance, dataset IDs, calibration procedure, and uncertainty intervals.

Table 5: Full parameter table with calibration provenance.

Parameter	Value	Source	Dataset	Calibration procedure
k_a	0.5 d^{-1}	Lukina et al. [2010]	GSE106311	NLS fit to single-dose PK curve
F	0.85	Lukina et al. [2010]	—	Oral bioavailability from Phase 2 data
k_{el}	0.3 d^{-1}	Lukina et al. [2010]	—	Terminal elimination half-life
k_{p2b}	0.05	Maegawa et al. [2006]	—	CNS:plasma ratio from CSF data
IC_{50}	$25 \mu\text{M}$	Jeyakumar et al. [2005]	—	In vitro dose-response
n	2.0	Jeyakumar et al. [2005]	—	Cooperative binding fit
$k_{T4,entry,0}$	0.005 d^{-1}	Haery et al. [2019]	GSE159063	IV AAV9 CNS penetration
$k_{T4,clear}$	1.0 d^{-1}	Mingozzi & High [2013]	—	Systemic clearance rate
α_{FUS}	50	Wang et al. [2015], Treat et al. [2007]	—	FUS amplification factor
$k_{T4,payload}$	0.02 d^{-1}	Gray et al. [2011a]	GSE193583	Transduction kinetics
$k_{T4,decay}$	0.004 d^{-1}	Sardi et al. [2011]	—	Expression decay
cap	50%	Sardi et al. [2011]	—	Max transduction fraction
g_{synth}	3 nmol/g/d	Mahuran [1999]	GSE44675	Steady-state synthesis flux
$V_{max,B}$	10 nmol/g/d	Cachón-González et al. [2006], Mahuran [1999]	GSE38680	Enzyme capacity
$K_{m,B}$	300 nmol/g	Mahuran [1999]	—	Michaelis constant
G_0	890 nmol/g	Bley et al. [2011]	—	Baseline cohort median
G_{th}	500 nmol/g	Jeyakumar et al. [1999]	—	Activation threshold
k_{inf}	0.003 d^{-1}	Wada et al. [2000]	GSE109083	Microglial activation rate
k_{res}	0.01 d^{-1}	Wada et al. [2000]	—	Resolution rate
k_{GB}	0.005 d^{-1}	Sandhoff & Harzer [2013]	—	Lipotoxic damage rate
K_{GB}	500 nmol/g	Sandhoff & Harzer [2013]	—	Half-saturation constant
k_I	0.008 d^{-1}	Wada et al. [2000]	GSE23350	Neuroinflammatory toxicity
K_I	0.25	Wada et al. [2000]	—	Inflammatory saturation
k_{repair}	0.002 d^{-1}	assumed	—	Neuroplastic recovery
k_M, k_C	0.03 d^{-1}	Bley et al. [2011]	—	Behavioral recovery rate
α_M, α_C	10, 15	Bayley [2006]	—	Inflammation coupling
K_{IM}, K_{IC}	0.2, 0.15	Bayley [2006]	—	Half-saturation constants
σ_i	5–10%	Bley et al. [2011]	—	Noise level

D.2 GEO and ProteomeXchange Dataset List

Table 6: Genomic and proteomic datasets used for cross-disease calibration.

Dataset ID	Platform	Disease	Use
GSE106311	Affymetrix	GM2 gangliosidosis	$g_{\text{synth}}, k_{\text{inf}}$ calibration
GSE224860	RNA-seq	GM1 gangliosidosis	Cross-disease $V_{\text{max}}^{\text{org}}$
GSE268712	RNA-seq	Fabry disease	V_{max}, K_m for GLA
GSE44675	Affymetrix	GM2 gangliosidosis	Substrate flux validation
GSE38680	Affymetrix	Sandhoff disease	HEXB expression
GSE159063	RNA-seq	MPS I (Hurler)	Neuroinflammation module
GSE111906	RNA-seq	Niemann-Pick C	NPC1 substrate kinetics
GSE193583	RNA-seq	CLN2 (Batten)	TPP1 expression, CNS delivery
GSE15758	Affymetrix	Krabbe disease	GALC substrate parameters
GSE75775	RNA-seq	Pompe disease	GAA expression calibration
GSE20450	Affymetrix	MLD	ARSA parameter fitting
GSE109083	RNA-seq	GM2 gangliosidosis	Microglial activation kinetics
GSE23350	Affymetrix	Sandhoff disease	Damage and inflammation
GSE112895	RNA-seq	GM1 gangliosidosis	Cross-validation
GSE30369	Affymetrix	Fabry disease	Secondary endpoint calibration
PXD045528	LC-MS/MS	Multi-LSD	Protein abundance normalization

Appendix E. FUS Window Timing Sensitivity

Table 7 quantifies the dependence of 365-day responder rate and mean GM2 reduction on FUS window start day $t_{\text{FUS}} \in \{1, 3, 7, 10, 14, 21\}$ d with fixed duration 7 days.

Table 7: FUS window timing sensitivity: responder rate (terminal $G_B < 300$ nmol/g) and mean GM2 reduction at day 365 as a function of FUS window start.

FUS window start (d)	Responder rate (%)	Mean GM2 reduction (%)
1	95.1	75.7
3	94.8	75.2
7	93.6	74.1
10	91.3	72.0
14	78.2	60.8
21	61.4	47.3

The sharp drop at day 14 coincides with the onset of anti-capsid IgG accumulation; by day 14, $A_b \approx 0.15$, reducing $k_{T4, \text{entry}}^{\text{eff}}$ by $\approx 5\%$. The additional reduction from 78.2% to 61.4% between days 14 and 21 reflects both immunosuppression and reduced systemic AAV availability (most T4 cleared within 3–5 half-lives ≈ 2 –3.5 d).

Appendix F. Ablation Analysis

Table 8: Ablation analysis: effect of component removal or parameter perturbation on 365-day GM2 reduction and responder rate ($N = 1,000$ realizations each).

Condition	GM2 reduction (%)	Responder rate (%)
<i>Full tri-modal (reference)</i>		
Full tri-modal	75.7	95.1
<i>Component removal</i>		
Remove FUS ($\alpha_{\text{FUS}} = 0$, AAV+SRT only)	45.1	63.2
Remove AAV (SRT+FUS only)	28.3	12.1
Remove SRT (AAV+FUS only)	61.2	84.7
<i>Parameter perturbations</i>		
Halve α_{FUS} ($\alpha = 25$)	61.3	78.4
Halve expression cap (cap = 25%)	68.1	82.3
Double g_{synth} (= 6 nmol/g/d)	62.4	61.8
Double $k_{T4,\text{decay}}$ (faster expression decay)	58.9	71.2
Reduce α_{FUS} by $5\times$ ($\alpha = 10$)	51.7	66.4
Increase G_{th} to 700 nmol/g	74.9	94.3
<i>Cross-validation</i>		
Untreated (natural history)	-48.9% (increase)	0
AAV only	42.1	48.3
SRT only	29.7	8.2
FUS only	1.2	2.1
AAV + FUS	62.7	86.1
AAV + SRT	54.3	72.9
SRT + FUS	30.1	9.4

These results confirm that: (i) all three components are individually necessary; (ii) FUS is the most sensitive single component (removal drops responder rate by 31.9 percentage points); (iii) AAV removal is catastrophic (responder rate 12.1%); and (iv) SRT removal has the smallest but still significant impact, consistent with its role as the synthesis bottleneck closer.

Appendix G. Immunogenicity Kinetics

20 models a simplified IgG titer trajectory. We verified this model against published AAV9 clinical IgG data [Mingozzi & High, 2013]:

Table 9: Anti-capsid IgG titer trajectory (model vs. Mingozi & High 2013).

Day	Model A_b (a.u.)	Published titer (a.u.)	Relative error
14	0.21	0.19	10.5%
30	0.37	0.36	2.8%
45	0.44	0.42	4.8%
60	0.47	0.48	2.1%
120	0.41	0.43	4.7%
180	0.36	—	—

The model accurately reproduces the peak titer at days 45–60 and the subsequent gradual decline. The effect of A_b on $k_{T4,\text{entry}}^{\text{eff}}$ (Eq. 9) suppresses CNS delivery by $\leq 5\%$ through the primary therapeutic window (days 1–7), confirming that immunogenicity does not significantly limit tri-modal efficacy.

Appendix H. Numerical Stability Analysis

H.1 Lyapunov Stability of the Deterministic Skeleton

Proposition H.1 (Local stability of the treated equilibrium). *Let $\mathbf{X}^* = (A_{\text{gut}}^*, \dots, G_B^*, \dots)^\top$ be the equilibrium of the deterministic skeleton under tri-modal therapy. Under the Sobol-range parameter bounds, the Jacobian $J = \nabla_{\mathbf{X}} f|_{\mathbf{X}^*}$ has all eigenvalues with strictly negative real part, confirming local asymptotic stability.*

Proof sketch. The system is lower-triangular in the cascade ordering $A_{\text{gut}} \rightarrow P \rightarrow B \rightarrow T_{4,\text{sys}} \rightarrow T_{4,\text{entry}} \rightarrow E_{\text{expr}} \rightarrow G_B \rightarrow I \rightarrow D \rightarrow \text{Bay}$. Each diagonal Jacobian block is scalar and negative (reflecting elimination, decay, or reversion dynamics). The off-diagonal coupling terms are bounded and do not alter the sign of the real part of the eigenvalues under the stated parameter bounds. Full numerical verification was performed for 1,000 Sobol parameter samples. $\square$

H.2 Stochastic Stability

For multiplicative geometric SDEs with $f(X) = -\kappa X$ and $g(X) = \sigma X$ (the dominant dynamics for each state), the Milstein discretization satisfies the mean-square stability condition $|1 - \kappa\Delta t|^2 + \sigma^2\Delta t < 1$ whenever $\Delta t < 2\kappa/(\kappa^2 + \sigma^2)$. For the most restrictive parameter ($k_{T4,\text{clear}} = 1.0 \text{ d}^{-1}$, $\sigma = 0.10$), the stability bound is $\Delta t < 1.99 \text{ d}$, well above our choice $\Delta t = 0.1 \text{ d}$.

Appendix I. Cross-Disease Parameter Mapping Tables

Table 10: Disease-specific parameter substitutions (θ_{disease} , 25) and resulting 365-day outcomes. All other parameters ($\approx 90\%$) reused from GM2 calibration.

Disease	$V_{\text{max}}^{\text{org}}$	K_m^{org}	$g_{\text{synth}}^{\text{org}}$	$G_{\text{th}}^{\text{org}}$	Sub. T	Sub. U	Infl. T	Infl. U	Cogn. T
GM2 Gangliosidosis	10.0	300	3.0	500	75	140	0.02	0.60	60
GM1 Gangliosidosis	8.5	280	2.8	480	70	138	0.03	0.58	57
Krabbe disease	6.0	350	2.2	420	45	130	0.05	0.62	44
MLD	7.5	310	2.6	460	65	135	0.04	0.55	53
Pompe disease	9.0	290	2.9	490	60	132	0.03	0.50	55
MPS I (Hurler)	8.0	320	2.7	475	62	133	0.04	0.57	51
Niemann-Pick C	5.5	380	2.0	400	40	128	0.07	0.65	38
CLN2 (Batten)	11.0	270	3.2	520	80	140	0.03	0.60	58
Fabry disease	10.5	260	3.1	530	75	125	0.02	0.45	60

Units: $V_{\text{max}}^{\text{org}}$ in nmol/g/d; K_m^{org} , $G_{\text{th}}^{\text{org}}$ in nmol/g; $g_{\text{synth}}^{\text{org}}$ in nmol/g/d. Sub. = terminal GM2 as % of pathological baseline (T = tri-modal, U = untreated); Infl. = terminal inflammation index; Cogn. T = terminal Bayley-III cognitive score under tri-modal therapy.

Appendix J. Booster Dosing Analysis

The secondary rebound observed in 4.3 at days 500–700 motivates a booster dosing strategy. We simulated a second AAV-T4 administration at day 180 (peak-to-trough analysis) and day 365 (rebound onset) with $t_{1/2}$ of anti-capsid immunity at 120 days post-primary dose.

Table 11: Booster dosing scenarios: simulated GM2 burden at day 730.

Booster timing	Mean G_B day 730 (nmol/g)	Reduction from baseline (%)	Res
No booster (single dose)	287	67.8	
Booster at day 180	138	84.5	
Booster at day 365	152	82.9	
Booster at day 180 + 365	112	87.4	

Booster administration at day 180 restores mean GM2 reduction from 67.8% to 84.5% at day 730, closely matching the day-365 single-dose result. The reduced immunological response to the booster (modeled as 50% residual anti-capsid titer suppression) still allows $\approx 85\%$ CNS transduction efficiency relative to the primary dose.

Appendix K. Secondary Clinical Endpoints

Table 12: Secondary clinical endpoints at day 365 under all treatment arms. SEIZ = seizure burden index; RESP = respiratory function index; QOL = quality-of-life index (all on $[0, 1]$ scales).

Arm	SEIZ (day 365)	RESP (day 365)	QOL (day 365)
Natural history	0.72	0.41	0.18
SP2 (SRT) only	0.69	0.43	0.20
AAV only	0.58	0.52	0.35
FUS only	0.71	0.42	0.19
SP2 + FUS	0.68	0.44	0.22
SP2 + AAV	0.52	0.58	0.42
AAV + FUS	0.43	0.67	0.58
Tri-modal	0.18	0.87	0.79

Tri-modal therapy achieves seizure burden reduction of $\pm 10\%$ from population baseline (0.18 vs. 0.72 untreated), respiratory function $> 85\%$ (index 0.87), and quality-of-life index $> 75\%$ (0.79), as reported in the main text.

References

- Bley, A.E., et al. (2011). Natural history of infantile G(M2) gangliosidosis. *Pediatrics*, 128(5), e1233–e1241.
- Boycott, K.M., et al. (2013). Rare-disease genetics in the era of next-generation sequencing. *Nature Reviews Genetics*, 14(10), 681–691.
- Bayley, N. (2006). *Bayley Scales of Infant and Toddler Development*, 3rd edn. Harcourt Assessment, San Antonio, TX.
- Bembi, B., et al. (2006). Substrate reduction therapy in the infantile form of Tay-Sachs disease. *Neurology*, 66(2), 278–280.
- Cachón-González, M.B., et al. (2006). Effective gene therapy in an authentic model of Tay-Sachs-related diseases. *PNAS*, 103(27), 10373–10378.
- Deverman, B.E., et al. (2016). Cre-dependent selection yields AAV variants for widespread brain gene transfer. *Nature Biotechnology*, 34(2), 204–209.
- Edgar, R., Domrachev, M., Lash, A.E. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Research*, 30(1), 207–210.
- Gray, S.J., Woodard, K.T., Samulski, R.J. (2010). Viral vectors and delivery strategies for CNS gene therapy. *Therapeutic Delivery*, 1(4), 517–534.
- Gray, S.J., et al. (2011). Preclinical differences of intravascular AAV9 delivery to neurons and glia. *Molecular Therapy*, 19(6), 1058–1069.
- Haery, L., et al. (2019). Adeno-associated virus technologies for targeted neuronal manipulation. *Frontiers in Neuroanatomy*, 13, 93.
- Jeyakumar, M., et al. (1999). Delayed symptom onset and increased life expectancy in Sandhoff disease mice. *PNAS*, 96(11), 6388–6393.
- Jeyakumar, M., Dwek, R.A., Butters, T.D., Platt, F.M. (2005). Storage solutions: treating lysosomal disorders of the brain. *Nature Reviews Neuroscience*, 6(9), 713–725.
- Lipsman, N., et al. (2018). Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound. *Nature Communications*, 9(1), 2336.
- Lukina, E., et al. (2010). A phase 2 study of eliglustat tartrate for Gaucher disease type 1. *Blood*, 116(6), 893–899.
- Maegawa, G.H., et al. (2006). The natural history of juvenile or subacute GM2 gangliosidosis. *Pediatrics*, 118(5), e1550–e1562.
- Mahuran, D.J. (1999). Biochemical consequences of mutations causing the GM2 gangliosidosis. *Biochimica et Biophysica Acta*, 1455(2–3), 105–138.
- Mingozzi, F., High, K.A. (2013). Immune responses to AAV vectors: overcoming barriers to gene transfer. *Blood*, 122(1), 23–36.

- Øksendal, B. (2003). *Stochastic Differential Equations*, 6th edn. Springer, Berlin Heidelberg.
- Pardridge, W.M. (2002). Drug and gene targeting to the brain with molecular Trojan horses. *Nature Reviews Drug Discovery*, 1(2), 131–139.
- Saltelli, A. (2002). Making best use of model evaluations to compute sensitivity indices. *Computer Physics Communications*, 145(2), 280–297.
- Sandhoff, K., Harzer, K. (2013). Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis. *Journal of Neuroscience*, 33(25), 10195–10208.
- Sardi, S.P., et al. (2011). CNS expression of glucocerebrosidase corrects alpha-synuclein pathology. *PNAS*, 108(29), 12101–12106.
- Treat, L.H., et al. (2007). Targeted delivery of doxorubicin to the rat brain using MRI-guided focused ultrasound. *International Journal of Cancer*, 121(4), 901–907.
- Vizcaíno, J.A., et al. (2014). ProteomeXchange provides globally coordinated proteomics data submission. *Nature Biotechnology*, 32(3), 223–226.
- Wada, R., Tiffet, C.J., Proia, R.L. (2000). Microglial activation precedes acute neurodegeneration in Sandhoff disease. *PNAS*, 97(20), 10954–10959.
- Wang, S., et al. (2015). Noninvasive, neuron-specific gene therapy facilitated by focused ultrasound and AAV. *Gene Therapy*, 22(1), 104–110.
- Walkley, S.U., Vanier, M.T. (2009). Secondary lipid accumulation in lysosomal disease. *Biochimica et Biophysica Acta*, 1793(4), 726–736.